亚太未活跃的bladder市场份额、未来分析和工业规模

Asia Pacific Underactive Bladder Market

市场规模（十亿美元）

CAGR : 6.00 %

USD 420.00 Million USD 669.41 Million 2025 2033

Forecast Period	2026 –2033
Market Size (Base Year)	USD 420.00 Million
Market Size (Forecast Year)	USD 669.41 Million
CAGR	6.00 %
Major Markets Players	Astellas Pharma Inc. (日本) 波士顿科学公司(美国) Coloplast Corp (丹麦) Convatec Group PLC (英国) Cook (美国).

亚太低活性Bladder市场,按类型(药物疗法、外科手术方法、排泄物辅助装置、以及死细胞和基因疗法)、管理路线(Oral、Patheral等)、疾病类型(神经致病性低活性Bladder和非神经致病性低活性Bladder)、分发渠道(医院药房、零售药房等) 2033年工业趋势和预测

亚太低活性刀锋市场概况

亚太活性不足的膀胱市场价值2025年4.2亿美元预计将达到到2033年达到6.6941亿美元,生长在一个2026年至2033年CAGR为6.0%.15. 市场正稳步增长,原因是与衰老有关的泌尿道疾病日益普遍,人们对尿道功能不良的认识不断提高,以及亚洲新兴经济体更容易获得先进的诊断和治疗解决方案。

老年人口的增长、神经致性膀胱失调、与糖尿病有关的泌尿并发症和脊髓损伤的发生率的上升,都极大地推动了市场需求。此外,扩大保健基础设施,更多地采用侵入性最小的泌尿道治疗,增加对泌尿道护理的投资,都鼓励医院和专科诊所实施先进的膀胱管理疗法。中国、日本、印度和韩国等国越来越多地使用药理学治疗、神经调节技术和以导管为基础的管理方法,支持区域市场的长期扩展。

主要市场趋势和见解

中国主导了亚太地区的膀胱功能不足市场,2025年收入份额最大,为34.26%,其人口老化,泌尿科护理基础设施扩大,膀胱功能障碍疗法得到越来越多的采用。
2025年,受口服药物的广泛使用和膀胱功能失调的长期保守管理方法的驱动,药物疗法部分以39.84%的比重在市场领先.
印度预计将是增长最快的国家市场,2026年至2033年的CAGR市场为7.1%,这得益于卫生保健意识的提高、对诊断机会的改善以及对泌尿科治疗设施的投资的增加。
Stem Cell和基因疗法是增长最快的类型,预计将登记7.1%的CAGR,反映出专注于再生膀胱治疗解决方案的研究活动激增.
口服部分主导了2025年52.61%的收入占管理类别份额的路线,由患者强烈倾向于方便和非侵入性治疗方法.
非神经致病性低活性血浆症占市场的57.43%,更受与年龄有关的膀胱功能障碍和与糖尿病有关的泌尿道保留症发病率上升的影响。
父母部分是管理类别增长最快的途径,CAGR为6.8%,由越来越多的注射疗法和神经调节辅助治疗程序所驱动。

市场大小和预测

全球市场价值(2025):42.00亿美元
预期市场价值(2033年):6.6941亿美元
CAGR(2026-2033年):6.0%
2025年领先国家:中国
最快增长的国家:印度

报告范围和范围亚太未活跃的市场分割

属性	亚太低活性平板键市场透视
覆盖部分	按类型: 药物疗法、外科手术方法、泌尿辅助设备、化粪池和基因治疗按行政区划n: 口腔、家长和其他按疾病类型: 神经性低活性平板和无神经性低活性平板按发行频道: 医院药房、零售药房等
涵盖国家	亚太中国 * 日本 • 印度韩国新加坡马来西亚澳大利亚泰国印度尼西亚菲律宾亚太其他地区
关键市场玩家	• 妇女阿斯泰拉斯制药公司(日本) • 妇女波士顿科学公司(美国). • 妇女科洛普拉斯公司(丹麦) • 妇女召集组 PLC(吴. • 妇女厨师(美国). 霍利斯特公司(美国) B. Braun SE(德国) · 美敦尼克(爱尔兰) Teleflex公司(美国) 健康保健(瑞典) · 劳工医疗技术公司(加拿大) · 辉瑞公司(美国) • AbbVie公司(美国) · UroMems(法国) Axonics股份有限公司(美国) · C.R.Bard, Inc.(美国) * 奥林匹斯公司(日本) Fresenius医疗协会(德国) · Cogentix医疗公司(美国) · BD(美国)
市场机会	越来越多地采用圣体神经调节和可植入的膀胱刺激装置增加对再生医学和干细胞膀胱疗法的临床研究扩大家用导管产品和远程泌尿监测解决方案
添加数据信息集的值	除了对市场价值、增长率、分割、地理覆盖和主要角色等市场假设的深刻见解外,由数据桥市场研究编写的市场报告还包括深入的专家分析、病人流行病学、管道分析、定价分析和监管框架。

亚太未活跃的市场趋势

趋势:逐步采用最小侵入式刀具管理疗法

整个亚太区域的保健提供者越来越多地采用最低侵入性疗法来进行活动不足的膀胱管理,以改善病人的结果,减少住院时间并尽量减少程序并发症。萨克拉尔神经调节、电刺激装置和间歇性导管化技术,由于效果好,生活质量效益得到提高,在老年和神经致病膀胱患者中越来越受欢迎。医院和专科泌尿科中心也在整合数字监测技术和个性化治疗方法,以加强中国、日本、韩国和印度快速老龄化人口的长期泌尿护理管理。

例如,2024年3月,设在日本的保健机构扩大了对神经调节辅助膀胱功能障碍疗法的临床应用,以支持患有慢性泌尿功能障碍和尿道功能障碍较低的老年病人。

亚太未活跃的市场动态

主要市场驱动力:人口老龄化和尿道疾病发病率上升

整个亚太迅速扩大的老年病人口大大增加了膀胱功能不足、泌尿道留滞、与糖尿病有关的膀胱功能障碍和由神经引起的尿道紊乱等发病率。人们对小便道症状的认识日益提高,泌尿道诊断的获取机会也日益改善,这正在鼓励早期的疾病识别和治疗。各国政府和保健提供者还投资于先进的泌尿护理基础设施、康复服务和慢性病管理方案,支持更广泛地利用药物疗法、导管管理和神经调理技术。例如,2024年8月,韩国的保健当局推出了扩大的老年泌尿科护理举措,重点是改善与年龄有关的膀胱功能障碍的诊断和治疗。

主要限制/挑战:认识有限和先进治疗程序费用高

亚太区域膀胱功能不足市场的一个主要挑战是公众对膀胱功能障碍的认识有限,与先进治疗程序有关的费用相对较高。发展中经济体的许多病人仍然得不到诊断,原因是社会污名化、得不到足够的泌尿科专家、神经调节和长期膀胱管理疗法的保健报销有限。此外,先进的诊断设备、可植入的刺激系统以及后续护理要求增加了总的治疗费用,限制了低收入病人的广泛采用和较小的保健设施。

例如,2024年11月,一些东南亚保健组织报告说,由于对可移植膀胱刺激装置的可负担性的关切和农村治疗中心的报销支助有限,其采用率较慢。

关键市场机会:扩大高级泌尿护理和数字健康一体化

先进的泌尿科护理基础设施和数字保健技术的扩大为亚太活动不足的膀胱市场提供了巨大的增长机会。保健提供者越来越多地利用远程医疗平台、远程膀胱监测系统和AI辅助诊断工具来改进治疗规划和长期病人管理。对医院现代化、专科泌尿科诊所和康复中心的投资不断增加,进一步支持采用新型膀胱功能障碍疗法。印度、中国和印度尼西亚等新兴经济体预计将看到巨大的市场潜力,因为获得医疗保健的机会和提高认识方案将继续扩大。例如,2025年2月,印度多所医院实施了AI支持的泌尿功能障碍评估平台,旨在改善早期诊断和个人化膀胱治疗规划。

亚太未活跃的市场范围

亚太活性不足的膀胱市场按类型、管理路线、疾病类型和分配渠道划分。

按类型

根据类型,亚太活性不足的膀胱市场被划分为药理疗法、外科手术方法、尿道辅助装置以及干细胞和基因疗法。 2025年,由于广泛使用口服药物和对膀胱功能障碍采取长期保守的管理办法,药理治疗部分在市场上占有39.84%的份额。胆固醇剂、α阻塞剂和复方疗法在医院和泌尿科诊所中仍然普遍开具,因为它们的可获性和相对较低的治疗费用。在疾病管理的早期阶段,在考虑入侵性干预措施之前,药剂疗法往往更为可取。亚洲新兴经济体对小便道症状的认识不断提高并增加获得保健服务的机会,这也有助于部分增长。针对性泌尿道药物的不断研制和病人遵守规定的情况的改善正在加强治疗的采纳率。该部分继续受益于广泛的医生熟悉程度和整个区域扩大的药品分销网络。

预计Stem细胞和基因治疗部分在2026年至2033年的CAGR增长最快,为7.1%,其动力是越来越多的研究活动侧重于再生膀胱治疗解决方案。这些疗法正在引起人们的注意,因为它们有可能恢复膀胱肌肉萎缩,改善慢性活性不足的膀胱病人的长期泌尿功能。日本、中国和韩国的学术机构和生物技术公司正在大力投资再生医学发展方案。细胞治疗制造和基因输送系统的技术进步正在改善治疗的可行性和临床结果。对最低侵入性和可持久治疗替代品的需求正在进一步加快临床试验活动。增加政府对再生保健创新的支持,预计也将加强本区域今后的商业化机会。

按行政路线分列

根据管理路线,亚太活性不足的膀胱市场被分入口服,亲服等. 口服部分在2025年以52.16%的股权带动了市场,其驱动力是患者对方便和非侵入性治疗方法的强烈偏好. 由于管理方便,零售和医院药店广泛供应,口服药物被广泛用于膀胱功能障碍症状的长期管理. 与注射和外科手术相比,治疗费用较低,也使这一部分受益。医生经常建议将口服治疗作为轻度至中度性膀胱病的一线治疗方案。城市人口对泌尿道疾病的认识得到提高,获得保健服务的机会得到改善,这进一步支持了部门增长。通过扩大药品分销渠道持续提供产品,继续强化这一部门的支配地位。

由于越来越多地采用注射疗法和神经调节辅助治疗程序,父母部分在2026年至2033年期间的CAGR增长最快,为6.8%。在需要快速治疗和更高精度治疗的重度和耐治疗性膀胱功能障碍病例中,父母的治疗能力越来越强。生物疗法和再生医学方法方面的进步进一步推动了分化扩大。医院和专科泌尿科中心正越来越多地利用注射性干预措施和高级康复疗法。对专业保健基础设施和泌尿道服务的投资不断增加,加快了治疗的普及。临床上更加注重改善膀胱肌肉的长期恢复,预计在预测期间将进一步支持分块生长。

按疾病类型

根据疾病类型,亚太活性不足的膀胱市场被分入神经致病性活性不足的膀胱和非神经致病性活性不足的膀胱. 2025年,由于与年龄有关的膀胱功能障碍和与糖尿病有关的泌尿道保留障碍的发病率上升,非神经诱发性低活性血清部分占了市场的57.43%。由于慢性健康状况和与生活方式有关的疾病,亚太区域老年人的膀胱萎缩率正日益下降。非神经致病性膀胱功能障碍病例在一般泌尿科环境中被更常见地诊断出,导致治疗量较高. 公众对泌尿卫生的认识得到提高,诊断程序得到增加,这些都有助于早期的疾病检测。包括药物疗法和导管化在内的保守治疗方法仍然被广泛用于管理非神经致病条件。扩大中国、日本和韩国的老年保健方案,继续增加部分需求。

由于脊髓损伤、帕金森病、多发性硬化症和糖尿病性神经病的发病率不断上升,2026年至2033年的CAGR增长最快,为6.9%。神经病性膀胱病往往需要长期的专门治疗和持续监测,有助于提高保健利用率。神经调节疗法和康复技术的进步正在改善神经性膀胱功能障碍患者的治疗结果。医院和专科康复中心正在扩大对高级泌尿护理服务的投资,以满足病人日益增长的需求。提高对神经泌尿道并发症的认识,正在鼓励早期的干预和专家咨询。越来越多的以神经再生和膀胱刺激技术为重点的研究活动正在进一步加快市场增长。

按发行频道

根据分销渠道,亚太活动不足的膀胱市场分为医院药房,零售药房等. 医院药房部分在2025年以61.12%的比重领导了市场,其驱动力是在医院泌尿科部门内进行大量膀胱不活跃诊断和治疗。医院仍然是高级诊断、神经调节程序、导管干预和专家咨询的主要中心。这部分工作得益于医生的有力监督、多学科治疗小组的介入以及膀胱管理专门疗法的提供。患有严重或慢性泌尿功能障碍的患者往往依靠医院药房进行持续的处方管理和手术后护理. 亚太区域对三级卫生保健基础设施的投资不断增加,泌尿科专业服务不断扩大,这进一步支持了部门主导地位。老年病人住院率的提高继续强化这一分发渠道的长期需求。

2026年至2033年,由于口服膀胱功能障碍药物的普及范围扩大,消费者越来越倾向于方便的门诊治疗管理,零售药房部门预计增长最快,为6.7%。零售药店越来越多地提供处方补药服务、病人咨询和慢性病支助方案,以管理尿道障碍。整个亚洲新兴经济体的快速城市化和有组织的药店链的扩大正在改善药品的获取。越来越多地采用以家庭为基础的膀胱护理解决方案和间歇性导管化产品也促进了分块增长。数字药店平台和电子处方服务进一步加强了治疗的连续性和消费者的参与。预计对早期泌尿障碍治疗的认识将在整个预测期间继续支持零售药店的扩展。

亚太未活跃的市场市场区域分析

中国主导了亚太地区的膀胱功能不足市场,2025年收入份额最大,为34.26%,其人口老化,泌尿科护理基础设施扩大,膀胱功能障碍疗法得到越来越多的采用。该国还受益于保健支出的增加、对小便道疾病的认识的提高,以及城市和半城市保健设施获得诊断和康复服务的机会的改善。与糖尿病有关的泌尿道并发症和由神经引起的膀胱病的发病率不断上升,这继续推动医院和专科泌尿科中心的治疗需求。加大对最低侵入性疗法,神经调节技术,再生医学研究等投资力度,进一步加强了中国在亚太低活性膀胱市场的领导地位.

中国未活跃的布拉德市场透视

由于与年龄有关的泌尿道疾病发病率上升,保健投资增加,以及获得高级泌尿道治疗技术的机会扩大等原因,中国膀胱市场活跃度不足正在强劲增长。国内的老年人口众多,与糖尿病有关的膀胱功能失调的发生率不断上升,以及越来越多地采用侵袭性最小的治疗方法,这些都驱动着医院、专科诊所和康复中心的需求。此外,人们日益认识到尿道症状较低,而且神经调节和导管疗法的提供也越来越多,这正在加快城市和半城市保健设施的治疗。

日本未活跃的布拉德市场透视

由于对老年保健、高级泌尿技术以及膀胱康复方案的投资不断增加,日本的膀胱市场在持续增长。医院、专科泌尿科中心和研究机构越来越多地采用神经调节装置、再生医学疗法和先进的泌尿功能障碍管理系统。此外,数字保健监测技术的日益一体化以及该国注重改善老年病人护理结果,进一步促进了市场增长。

印度未活跃的布拉德市场透视

印度的膀胱不足市场正在稳步扩大,原因是改善了获得保健服务的机会,提高了对泌尿道疾病的认识,对负担得起的膀胱管理解决方案的需求也日益增加。医院和专科诊所越来越多地利用药物疗法、导管技术以及基于康复的治疗方法来解决病人人数不断增加的问题。保健基础设施的持续扩大、老年人口的增加以及政府对慢性病管理方案的日益重视,都进一步推动了整个印度的市场增长。

韩国未活跃的布拉德市场透视

韩国未活跃的膀胱市场在越来越多地采用先进的泌尿治疗技术、增加保健开支和扩大老年护理服务的支持下,正在稳步增长。保健提供者正在越来越多地实施最低侵入性膀胱管理程序和数字诊断平台,以提高治疗效率和病人结果。此外,对医疗创新、康复服务和个性化泌尿护理解决方案的大力投资正在将韩国定位为亚太活动不足的膀胱产业中以技术为驱动的关键市场。

亚太未活跃的布拉德市场份额

亚太未充分活跃的膀胱产业主要由历史悠久的公司领导,包括:

Astellas Pharma Inc.(日本)
波士顿科学公司(美国)
科洛普拉斯公司(丹麦)
Contratic Group PLC (英国).
库克 (美国).
霍利斯特公司(美国)
布劳恩·塞(德国)
梅德罗尼克(爱尔兰)
Teleflex公司(美国)
健康护理(瑞典)
Laborie医疗技术公司(加拿大)
辉瑞股份有限公司(美国)
AbbVie Inc. (美国).
乌罗梅斯(法国)
Axonics股份有限公司(美国)
R. Bard, Inc. (美国)
奥林匹斯公司(日本)
Fresenius Medical Care AG(德国)
Cogentix医疗股份有限公司(美国)
BD (美国).

亚太市场最新动态

2024年11月,由北京天丹医院和附属中医医疗机构的研究人员在"亚洲外科杂志"上发表研究报告,评价圣体神经调节结合3D印刷和超声局部化进行神经致病性膀胱治疗. 研究显示,骨盆结构异常患者的程序精度和治疗效率得到提高。发展重点突出中国各地膀胱功能障碍管理先进成像和个性化干预技术日益融合.
2024年10月,中国海军医科大学和广西大学的研究人员在"科学报告"上发表了研究结果,描述了一种新型的电能神经刺激方法,旨在模仿脊髓损伤模型中的反射性泌尿控制. 该研究表明,在神经致病性低泌尿道功能障碍和膀胱活性不足管理方面的电力刺激技术取得了重大进展。该研究支持亚太泌尿科部门日益重视先进神经调节疗法
2024年9月,在印度尼西亚举行的泛太平洋大陆学会(PPCS)2024年会议专门举行了关于分解性活性不足和高级膀胱功能障碍疗法的科学会议。活动包括来自日本、中国、台湾和广大亚太泌尿科协会的专家的互动讨论,重点是改进膀胱不足的治疗战略。会议表明,在与低尿道功能障碍管理有关的研究、临床创新和医师教育方面,区域合作不断加强。
2024年7月,以韩国为基地的正信制药获得食品药品安全部的IND批准,进行UIP-620第3期临床试验,这是下一代转基因泌尿功能障碍治疗平台. 与传统口服疗法相比,该疗法是利用先进的口服药物输送技术开发的,目的是提高长期治疗的合规性并减少副作用。发展反映出区域对新型膀胱失调症治疗办法的投资增加
2024年1月,Neurolief宣布其"Relivion"神经调节装置获得日本卫生,劳动和福利省批准供在家使用,标志着该国第一个被批准的"家用"神经调节平台. 该设备利用非侵入多通道神经刺激技术,并通过综合数字保健能力支持远程监测。核准强调了整个亚太越来越多地采用神经调节疗法进行神经和膀胱功能失调管理应用。

SKU-69095

在线获取全球首个市场情报云平台的报告访问权限

点击图片放大

交互式数据分析仪表板
用于发现高增长潜力机会的公司分析仪表板
研究分析师支持（定制与咨询）
带有交互式仪表板的竞争对手分析
最新新闻、更新与趋势分析
利用基准分析的强大功能，实现全面的竞争对手跟踪

申请演示

表格列表

TABLE 1 TOTAL 40 DOXAZOSIN DRUGS WERE DISCONTINUED FROM THE MARKET

TABLE 2 TOTAL 38 DOXAZOSIN DRUGS ARE STILL IN THE MARKET

TABLE 3 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (DOXAZOSIN) BY COMPANY

TABLE 4 TOTAL 58 DRUGS DISCONTINUED

TABLE 5 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (BETHANECHOL CHLORIDE) BY COMPANY

TABLE 6 OUT OF 3,128 STUDIES ON BLADDER DISORDER, ONLY 22 STUDIES ARE ONGOING FOR THE UAB-

TABLE 7 THESE CLINICAL TRIALS ARE MOSTLY RECRUITING/ONGOING IN DIFFERENT REGIONS OF THE WORLD-

TABLE 8 TOP ACQUISITIONS OF 2021 RANKED BY TOTAL DEAL VALUE:

TABLE 9 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED

TABLE 10 ASIA PACIFIC UNDERACTIVE BLADDER MARKET, TYPE, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 19 ASIA PACIFIC URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 ASIA PACIFIC URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 ASIA PACIFIC STEM CELL AND GENE THERAPIES IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 ASIA PACIFIC STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 23 ASIA PACIFIC UNDERACTIVE BLADDER MARKET , BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 24 ASIA PACIFIC PARENTERAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 ASIA PACIFIC ORAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 ASIA PACIFIC OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 ASIA PACIFIC UNDERACTIVE BLADDER MARKET , BY END USER, 2020-2029 (USD MILLION)

TABLE 28 ASIA PACIFIC HOSPITALS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 ASIA PACIFIC CLINICS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 ASIA PACIFIC ACADEMIC AND RESEARCH IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 ASIA PACIFIC OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 ASIA PACIFIC UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)

TABLE 33 ASIA PACIFIC HOSPITAL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 ASIA PACIFIC RETAIL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 ASIA PACIFIC OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 37 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 38 ASIA-PACIFIC PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 ASIA-PACIFIC PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 40 ASIA-PACIFIC BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 ASIA-PACIFIC BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 42 ASIA-PACIFIC BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 43 ASIA-PACIFIC BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 ASIA-PACIFIC BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 45 ASIA-PACIFIC BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 46 ASIA-PACIFIC BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 47 ASIA-PACIFIC SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 ASIA-PACIFIC URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 ASIA-PACIFIC STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 51 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 53 CHINA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 CHINA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 55 CHINA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 56 CHINA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 57 CHINA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 58 CHINA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 59 CHINA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 CHINA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 CHINA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 62 CHINA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 63 CHINA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 CHINA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 CHINA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 CHINA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 67 CHINA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 68 CHINA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 69 JAPAN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 70 JAPAN PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 71 JAPAN PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 JAPAN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 73 JAPAN BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 74 JAPAN BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 75 JAPAN BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 JAPAN BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 JAPAN BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 78 JAPAN BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 79 JAPAN SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 JAPAN URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 JAPAN STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 82 JAPAN UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 83 JAPAN UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 84 JAPAN UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 85 INDIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 86 INDIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 87 INDIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 88 INDIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 89 INDIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 90 INDIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 91 INDIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 INDIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 93 INDIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 94 INDIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 95 INDIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 96 INDIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 97 INDIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 98 INDIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 99 INDIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 100 INDIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 101 SOUTH KOREA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 102 SOUTH KOREA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 103 SOUTH KOREA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 104 SOUTH KOREA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 105 SOUTH KOREA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 106 SOUTH KOREA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 107 SOUTH KOREA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 108 SOUTH KOREA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 109 SOUTH KOREA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 110 SOUTH KOREA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 111 SOUTH KOREA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 112 SOUTH KOREA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 113 SOUTH KOREA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 114 SOUTH KOREA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 115 SOUTH KOREA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 116 SOUTH KOREA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 117 AUSTRALIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 118 AUSTRALIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 119 AUSTRALIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 120 AUSTRALIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 121 AUSTRALIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 122 AUSTRALIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 123 AUSTRALIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 124 AUSTRALIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 125 AUSTRALIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 126 AUSTRALIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 127 AUSTRALIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 128 AUSTRALIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 129 AUSTRALIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 130 AUSTRALIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 131 AUSTRALIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 132 AUSTRALIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 133 SINGAPORE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 134 SINGAPORE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 135 SINGAPORE PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 136 SINGAPORE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 137 SINGAPORE BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 138 SINGAPORE BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 139 SINGAPORE BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 140 SINGAPORE BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 141 SINGAPORE BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 142 SINGAPORE BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 143 SINGAPORE SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 144 SINGAPORE URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 145 SINGAPORE STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 146 SINGAPORE UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 147 SINGAPORE UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 148 SINGAPORE UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 149 THAILAND UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 150 THAILAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 151 THAILAND PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 152 THAILAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 153 THAILAND BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 154 THAILAND BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 155 THAILAND BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 156 THAILAND BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 157 THAILAND BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 158 THAILAND BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 159 THAILAND SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 160 THAILAND URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 161 THAILAND STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 162 THAILAND UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 163 THAILAND UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 164 THAILAND UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 165 INDONESIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 166 INDONESIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 167 INDONESIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 168 INDONESIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 169 INDONESIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 170 INDONESIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 171 INDONESIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 172 INDONESIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 173 INDONESIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 174 INDONESIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 175 INDONESIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 176 INDONESIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 177 INDONESIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 178 INDONESIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 179 INDONESIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 180 INDONESIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 181 PHILIPPINES UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 182 PHILIPPINES PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 183 PHILIPPINES PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 184 PHILIPPINES BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 185 PHILIPPINES BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 186 PHILIPPINES BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 187 PHILIPPINES BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 188 PHILIPPINES BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 189 PHILIPPINES BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 190 PHILIPPINES BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 191 PHILIPPINES SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 192 PHILIPPINES URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 193 PHILIPPINES STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 194 PHILIPPINES UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 195 PHILIPPINES UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 196 PHILIPPINES UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 197 MALAYSIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 198 MALAYSIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 199 MALAYSIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 200 MALAYSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 201 MALAYSIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 202 MALAYSIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 203 MALAYSIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 204 MALAYSIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 205 MALAYSIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 206 MALAYSIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 207 MALAYSIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 208 MALAYSIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 209 MALAYSIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 210 MALAYSIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 211 MALAYSIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 212 MALAYSIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 213 VIETNAM UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 214 VIETNAM PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 215 VIETNAM PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 216 VIETNAM BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 217 VIETNAM BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 218 VIETNAM BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 219 VIETNAM BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 220 VIETNAM BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 221 VIETNAM BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 222 VIETNAM BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 223 VIETNAM SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 224 VIETNAM URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 225 VIETNAM STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 226 VIETNAM UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 227 VIETNAM UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 228 VIETNAM UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 229 REST OF ASIA-PACIFIC UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE OF NEUROGENIC BLADDER INFECTIONS IS EXPECTED TO DRIVE THE ASIA PACIFIC UNDERACTIVE BLADDER MARKET IN THE FORECAST PERIOD

FIGURE 12 TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC UNDERACTIVE BLADDER MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA PACIFIC UNDERACTIVE BLADDER MARKET

FIGURE 14 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : TYPE, 2021

FIGURE 15 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : TYPE, 2022-2029 (USD MILLION)

FIGURE 16 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : TYPE, CAGR (2022-2029)

FIGURE 17 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : TYPE, LIFELINE CURVE

FIGURE 18 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2021

FIGURE 19 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 20 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 21 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 22 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY END USER, 2021

FIGURE 23 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY END USER, 2022-2029 (USD MILLION)

FIGURE 24 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY END USER, CAGR (2022-2029)

FIGURE 25 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY END USER, LIFELINE CURVE

FIGURE 26 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2021

FIGURE 27 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 28 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 29 ASIA PACIFIC UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 30 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)

FIGURE 31 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021)

FIGURE 32 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: BY COUNTRY (2022 & 2029)

FIGURE 33 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021 & 2029)

FIGURE 34 ASIA-PACIFIC UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)

FIGURE 35 ASIA PACIFIC UNDERACTIVE BLADDER MARKET: COMPANY SHARE 2021 (%)

查看详细信息

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。

常见问题

市场的增长率是多少?

在2029年的预测中,亚太未活跃的布拉德市场将以6.0%的CAGR增长。

谁是在市场上经营的主要角色?

在亚太低活性Bladder市场运营的主要角色有:Astellas Pharma Inc.,Aurobindo Pharma.,Boehringer Ingelheim International GmbH.,Macleods 医药有限公司,猎户座公司,ONO PHARMACEUTICAL CO.,LTD.,诺瓦尔蒂斯AG,Pfize Inc.,Cipla Inc.,Reddy's Laboratories Ltd.,Teva制药工业有限公司,太阳制药工业有限公司,Almirall,S.A.,以及Alkem Labs等.

市场增长繁荣的重要因素是什么?

亚太低活性Bladder市场增长所兴旺的重要因素是神经致病率的上升和保健支出的上升。

市场覆盖的主要国家是什么?

亚太低活性Bladder市场覆盖的主要国家有:日本,中国,印度,韩国,澳大利亚,新加坡,马来西亚,泰国,印度尼西亚,菲律宾,越南等,其余的亚太.

目前亚太活性不足的膀胱市场的规模是多少?

2025年,亚太未活跃的膀胱市场价值为4.20亿美元,预计到2033年将达到6.6941亿美元,2026至2033年CAGR增长6.0%。

亚太活动不足的膀胱市场的预期增长率是多少?

在2026至2033年的预测期内,受与衰老有关的泌尿道疾病发病率上升、对尿道功能不良的认识提高以及亚洲新兴经济体获得先进诊断和治疗解决方案的机会的推动,亚太区域的膀胱功能不足市场预计将增长6.0%。

哪个国家主导了亚太活动不足的膀胱市场?

中国主导了亚太地区的膀胱功能不足市场,2025年收入份额最大,为34.26%,其人口老化,泌尿科护理基础设施扩大,膀胱功能障碍疗法得到越来越多的采用。

亚太低活性膀胱市场增长最快的哪个国家?.

印度预计将是增长最快的国家市场,2026年至2033年的CAGR市场为7.1%,这得益于卫生保健意识的提高、对诊断机会的改善以及对泌尿科治疗设施的投资的增加。

亚太未活跃的市场规模、份额和趋势分析报告 -- -- 2033年工业概况和预测